Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery

CRS is a prognostic factor in PARPi-treated population as a PARPi efficacy surrogate. Integrating HRD status, CRS, and KELIM allows patients risk stratification and tailored maintenance. These results should be considered hypothesis-generating.

Authors

Institutions

Publication Details

Journal
Gynecologic Oncology
Published
2025-03-05
DOI
https://doi.org/10.1016/j.ygyno.2025.02.016
Citations
1
Primary Topic
PARP inhibition in cancer therapy
Type
article
Field-Weighted Citation Impact
1.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery

Aurore Carrot, Giovanni Scambia, Giancarlo Troncone, Olivier Colomban et al.
1 citations
Gynecologic Oncology
PARP inhibition in cancer therapy
1.05
article

Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery

Aurore Carrot, Giovanni Scambia, Giancarlo Troncone, Olivier Colomban, Luca Mastrantoni, Carolina Maria Sassu, Gian Franco Zannoni, Domenica Lorusso, Filippo Maria Capomacchia, Francesco Pepe, Cláudia Marchetti, Benoît You, Adriana Ionelia Apostol, Camilla Nero, Raffaella Ergasti, Diana Giannarelli, Gianluca Russo, Alessia Piermattei, Umberto Malapelle, Anna Fagotti
article en
1 citations

Abstract

CRS is a prognostic factor in PARPi-treated population as a PARPi efficacy surrogate. Integrating HRD status, CRS, and KELIM allows patients risk stratification and tailored maintenance. These results should be considered hypothesis-generating.

Gynecologic OncologyVol. 195
Université Claude Bernard Lyon 1 (FR), Università Cattolica del Sacro Cuore (IT), Lyon College (US), Agostino Gemelli University Polyclinic (IT), Hospices Civils de Lyon (FR), Associazione Italiana Di Oncologia Medica (IT), Centre de Recherche en Cancérologie de Lyon (FR), University of Naples Federico II (IT), HCL Technologies (India) (IN)
Zero hunger
Openalex Percentile: Top 25%
PARP inhibition in cancer therapy
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.